The Invesco Biotechnology & Genome ETF (PBE) seeks to replicate the performance of the Dynamic Biotech & Genome Intellidex Index. This fund typically allocates a minimum of 90% of its total assets to the securities comprising the underlying index. The Index is constructed to achieve capital appreciation by thoroughly evaluating companies based on several investment criteria, including their price momentum, earnings growth, overall quality, management decisions, and valuation. It consists of 30 U.S.-based companies within the biotechnology and genome sectors. These companies are primarily involved in the research, development, manufacture, and distribution of various biotechnological products, services, and processes, or they are businesses that stand to gain significantly from scientific and technological breakthroughs in biotechnology and genetic engineering. Both the ETF and its benchmark index undergo quarterly rebalancing and reconstitution in February, May, August, and November.

Amgen Inc.

Regeneron Pharmaceuticals, Inc.

Vertex Pharmaceuticals Incorporated

CareDx, Inc

Royalty Pharma plc

Biogen Inc.

Gilead Sciences, Inc.

Omeros Corporation

United Therapeutics Corporation

Halozyme Therapeutics, Inc.

Healthcare

Financial Services

Cash & Others

Invesco Biotechnology & Genome ETF

PBE Holdings & Sector Breakdown